alexa miRNA in clinical practice: pancreatic cancer.
Molecular Biology

Molecular Biology

Journal of Cytology & Histology

Author(s): Humeau M, Torrisani J, Cordelier P

Abstract Share this page

Abstract To date, pancreatic cancer (PDAC) can't be diagnosed early. Consequently, a majority of patient (80\%) display an advanced disease that results in a low resection rate leading to an overall median survival of 4 to 6months. Accordingly, robust markers for the early diagnosis and prognosis of pancreatic cancer, or markers indicative of survival and/or metastatic disease are desperately needed to help alleviate the dismal prognosis of this disease. In this chapter, we review the translational studies demonstrating that miRNAs, alone or in combination, may soon translate into clinical applications as long-awaited screening tools for PDAC. Copyright © 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved. This article was published in Clin Biochem and referenced in Journal of Cytology & Histology

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version